Spots Global Cancer Trial Database for her2 overexpression
Every month we try and update this database with for her2 overexpression cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer | NCT00401427 | Metastatic Brea... | trastuzumab vinorelbine | 18 Years - | National Cancer Institute, Naples | |
| Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer | NCT00615602 | Breast Cancer | Docetaxel Trastuzumab Epirubicin Cyclophosphamid... 5-fluoruracil Granulocyte-col... Trastuzumab | 18 Years - 75 Years | Hellenic Oncology Research Group | |
| A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression | NCT04714190 | Gastric Cancer HER2 Overexpres... | RC48-ADC Paclitaxel inje... Irinotecan Hydr... Apatinib Mesyla... | 18 Years - | RemeGen Co., Ltd. | |
| A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression | NCT04714190 | Gastric Cancer HER2 Overexpres... | RC48-ADC Paclitaxel inje... Irinotecan Hydr... Apatinib Mesyla... | 18 Years - | RemeGen Co., Ltd. | |
| A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2 | NCT03556345 | Gastric Cancer HER2 Overexpres... | RC48-ADC | 18 Years - 70 Years | RemeGen Co., Ltd. | |
| DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01] | NCT03329690 | Neoplasm, Gastr... | DS-8201a Physician's Cho... | 20 Years - | Daiichi Sankyo | |
| HER2 and LA/mUC: A Multi-country Chart Review Cohort Study | NCT05902494 | Urothelial Carc... | 18 Years - | Seagen Inc. | ||
| A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. | NCT04209465 | Solid Tumor | BDTX-189 | 18 Years - | Black Diamond Therapeutics, Inc. | |
| DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01] | NCT03329690 | Neoplasm, Gastr... | DS-8201a Physician's Cho... | 20 Years - | Daiichi Sankyo | |
| A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | NCT04879329 | Urothelial Carc... | disitamab vedot... pembrolizumab | 18 Years - | Seagen Inc. | |
| ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | NCT06328738 | HER2-positive B... HER2-positive G... HER2 Positive S... HER2 Amplificat... Colorectal Canc... | ELVN-002 Trastuzumab 5-Fluorouracil Oxaliplatin Capecitabine Eribulin paclitaxel Leucovorin | 18 Years - | Enliven Therapeutics | |
| ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | NCT06328738 | HER2-positive B... HER2-positive G... HER2 Positive S... HER2 Amplificat... Colorectal Canc... | ELVN-002 Trastuzumab 5-Fluorouracil Oxaliplatin Capecitabine Eribulin paclitaxel Leucovorin | 18 Years - | Enliven Therapeutics | |
| A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | NCT04879329 | Urothelial Carc... | disitamab vedot... pembrolizumab | 18 Years - | Seagen Inc. | |
| ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | NCT06328738 | HER2-positive B... HER2-positive G... HER2 Positive S... HER2 Amplificat... Colorectal Canc... | ELVN-002 Trastuzumab 5-Fluorouracil Oxaliplatin Capecitabine Eribulin paclitaxel Leucovorin | 18 Years - | Enliven Therapeutics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
